Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

CLYM Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Climb Bio, Inc.NASDAQ: CLYM

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$186K.

Context

  • Capital expenditures increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$46.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$186K— YoY
LTMMar 2026
-$186K— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(186K) USD
Year-over-year change
—

Capital Expenditures vs competitors

How CLYM compares with its peers on the latest reported figures

  • CLYM's LTM Mar 2026 capital expenditures of $186K is the 2nd largest of the 5 companies compared; the peer median is $67K.
CLYM Competitors Peer median
Capital Expenditures for CLYM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CABACabaletta Bio, Inc.LTM Mar 2026$444K -79.7%-20.6%—
CLYMClimb Bio, Inc.LTM Mar 2026$186K ———
TRAXFirst Tracks Biotherapeutics IncFY2025$87K -75.7%——
UPBUpstream Bio, Inc.LTM Mar 2026$47K -90.8%+26.2%1.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding CLYM) $67K-79.7%+2.8%1.4%

Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Depreciation & Amortization000097K
Deferred Income Tax00000
Stock-Based Compensation3.74M6.99M12.81M5.56M8.05M
Change in Working Capital(4.17M)210K3.76M1.7M(601K)
Accounts Receivables00000
Inventory00000
Accounts Payables318K(653K)(686K)(1.14M)1.56M
Other Working Capital(4.49M)863K4.45M2.84M(2.17M)
Other Non-Cash Items11.84M674K(2.05M)51.08M(2.06M)
Operating Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.36M)
Capital Expenditures0000(186K)
Acquisitions (Net)00000
Purchases of Investments(114.97M)(87.96M)(58.45M)(132.2M)(108.08M)
Sales of Investments0122.4M127.43M20.75M111.1M
Other Investing Activities000(9.65M)0
Investing Cash Flow(114.97M)34.44M68.98M(121.09M)2.83M
Debt Repayment00000
Common Stock Issued83.14M0841K119.75M(21K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities149K0010.98M0
Financing Cash Flow177.23M0841K130.73M(21K)
Effect of Forex Changes245K(408K)304K42K0
Net Change in Cash26.44M(3.34M)49.53M(5.88M)(51.54M)
Free Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.54M)

Climb Bio, Inc.

NASDAQ:CLYM

Intrinsic Alpha fair value

Locked

Current Price

$9.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.